Flexcin Joint/Pain Solution Launches to Retail Market
Meyers FL, 2 December 2003
International, Inc. today announced the retail marketing launch
of Flexcin, their new dietary supplement for joint health and mobility
with the patented compound, CM8.
(Cetyl Myristoleate), the most powerful anti-inflammatory ingredient
in Flexcin, was specially developed to improve patient recovery
rates. Flexcin International required eight specific "markers" to
achieve the desired effectiveness level that gives Flexcin its market
superiority. Other specially developed, market-superior Flexcin
ingredients include 120 mg of highly-refined Collagen Type II, their
high-end custom-formulated Glucosamine complex for easier absorption
into the bloodstream and enhanced for easy tolerance MSM.
is clinically proven to improve joint health for Americans of all
ages," said Tamer Elsafy, CEO/President. Flexcin has begun a vigorous
national radio and print advertising program in addition to a targeted
national publicity campaign.
in the United States in an FDA approved facility, Flexcin reverses
the progress of degenerative joint disorders, acts as a rheumatic
lubricant, functions as a powerful anti-inflammatory agent, performs
as an analgesic, boosts the immune system, and helps rebuild damaged
cartilage and promote healing.
is a natural alternative that can be used in a broad range of conditions,"
stated practicing internist and medical journalist, Dr. David Vastola.
"It is inexpensive, easy to take, the body tolerates it well and
it has CM8. It works! I am not aware of any other product like it."
International, Inc. (www.flexcin.com).